<DOC>
	<DOCNO>NCT01053858</DOCNO>
	<brief_summary>To evaluate effect intravitreal bevacizumab intravitreal triamcinolone treatment central retinal vein occlusion ( CRVO ) present poor visual acuity .</brief_summary>
	<brief_title>Triamcinolone Bevacizumab Central Retinal Vein Occlusion With Poor Vision</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>central macular thickness 250 Î¼m baseline visual acuity 20/200 bad 20/200 patient central retinal vein occlusion previous treatment intravitreal injection , subtenon injection , laser photocoagulation since time onset Patients history glaucoma , neovascular glaucoma , diabetic retinopathy , macular disorder neovascularization disc elsewhere rubeosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>bevacizumab , triamcinolone , intravitreal injection</keyword>
</DOC>